Precision Timelines: Navigating the Next Era of Nuclear Medicine

With over 20 years of leadership in healthcare supply chains, Larry Glasscock serves as Senior Manager of Radiopharmaceutical Operations at Marken UPS Healthcare Precision Logistics. He previously served on the Executive Leadership Team at MNX Logistics, and through its acquisition by UPS Healthcare brings deep expertise in the growing radiopharmaceutical sector.

A recognized authority in global supply chain resilience, Larry has led pivotal workshops for the National Academies of Sciences, Engineering, and Medicine and provided critical insights on maximizing the impact of the US Strategic National Stockpile. By merging his decades of operational experience with cutting-edge digital strategy, Larry continues to redefine how the industry delivers life-saving precision medicine on a global scale.

Ruben Bakker is Director of Business Development for Nuclear Medicine Logistics in EMEA at Marken, UPS Healthcare Precision Logistics. Skilled in orchestrating highly complex environments, he honed his expertise at MNX, continuing his leadership following its acquisition by UPS. Ruben brings over a decade of experience managing zero-margin-for-error, time-critical supply chains and, with his radiopharma expertise, ensures seamless execution while strengthening customer relationships and fostering strategic alliances. Driven by innovation, he is also developing an AI-powered operational intelligence platform designed to help logistics teams make faster, more consistent supply chain decisions. Ruben’s professional career is complemented by an academic foundation in life sciences and aviation.

Brandon Xiong serves as Board Member and Vice President of Technical Operations at CyGen Alpha Systems, where he leads operational strategy, execution, and organizational growth. He drives cost-efficient manufacturing strategies and oversees core operations across supply chain coordination, complex logistics, strategic partnerships, process optimization, and commercialization initiatives. Brandon plays a key role in advancing CyGen’s radiopharmaceutical capabilities, with a focus on critical medical isotopes such as Astatine-211 for targeted alpha therapy. 

Meg Mills is a Business Development Analyst at Niowave, where she focuses on strategic partnerships and program coordination in support of targeted alpha therapy development. Her work spans alliance management, supply planning, and cross-functional execution, helping bridge technical teams with partner needs across the radiopharmaceutical value chain.

Meg plays a key role in supporting isotope supply programs, including Actinium-225 initiatives, working closely with partners to navigate clinical development requirements and evolving demand. With a background in data-driven analysis and partner engagement, she brings a practical, detail-oriented approach to aligning production capabilities with real-world program needs.